Background: Acute kidney injury associated with proteinuria has been reported following vaccination against SARS-CoV-2 several times since 2021. Decisions about subsequent revaccination in these patients have been difficult because of the uncertainty of the consequences of doing so, and the absence of publications to help determine whether revaccination may be considered safe or not. Purpose: We present a case report of a 59-year-old Canadian man who developed severe acute kidney injury associated with moderate proteinuria following his first COVID-19 vaccine with the Moderna vaccine (an mRNA vaccine). He required haemodialysis for 2 weeks, which was initiated when his creatinine reached 1002 μmol/l. A kidney biopsy showed changes consistent with acute tubular necrosis. The patient was cautioned that repeat vaccination might result in further kidney injury which might be irreversible. However, he badly wanted to attempt a second COVID-19 vaccination, to facilitate a family vacation across several countries in Europe, at a time when travel restrictions were in place in many countries for persons who had not completed a course of vaccines. Method: Following deliberations, the patient chose to try a different type of Covid-19 vaccine. On this occasion, he was vaccinated with the Novavax vaccine (a subunit COVID-19 vaccine). Following this, close monitoring of his urine to detect proteinuria and blood testing for acute kidney injury were carried out on days 1, 3, 7, and 60 after vaccination. Furthermore, a year after his repeat vaccination, his kidney function and urinalysis were again assessed. Result and Conclusions: The patient did not develop acute kidney injury or worsening proteinuria following repeat vaccination. It remains unclear if acute kidney injury with proteinuria is caused by Covid-19 vaccination, or simply an incidental association. This case report suggests that it is may be reasonable for patients with acute kidney injury after COVID-19 vaccination to consider trying a different type of vaccine. In situations where a new virulent strain of virus emerges or in patients at risk of severe complication from infection, it may be reasonable to consider revaccination following appropriate counselling with close monitoring of renal function.
References
[1]
Lebedev, L., Sapojnikov, M., Wechsler, A., Varadi-Levi, R., Zamir, D., Tobar, A., Levin-Iaina, N., Fytlovich, S. and Yagil, Y. (2021) Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine. American Journal of Kidney Diseases, 78, 142-145. https://doi.org/10.1053/j.ajkd.2021.03.010
[2]
D’Agati, V.D., Kudose, S., Bomback, A.S., Adamidis, A. and Tartini, A. (2021) Minimal Change Disease and Acute Kidney Injury Following the Pfizer-BioNTech COVID-19 Vaccine. Kidney International, 100, 461-463. https://doi.org/10.1016/j.kint.2021.04.035
[3]
Hanna, J., Ingram, A. and Shao, T. (2021) Minimal Change Disease After First Dose of Pfizer-BioNTech COVID-19 Vaccine: A Case Report and Review of Minimal Change Disease Related to COVID-19 Vaccine. Canadian Journal of Kidney Health and Disease, 8. https://doi.org/10.1177/20543581211058271
[4]
Holzworth, A., Couchot, P., Cruz-Knight, W. and Brucculeri, M. (2021) Minimal Change Disease Following the Moderna mRNA-1273 SARS-CoV-2 Vaccine. Kidney International, 100, 463-464. https://doi.org/10.1016/j.kint.2021.05.007
[5]
Thappy, S., Thalappil, S.R., Abbarh, S., Al-Mashdali, A., Akhtar, M. and Alkadi, M.M. (2021) Minimal Change Disease Following the Moderna COVID-19 Vaccine: First Case Report. BMC Nephrology, 22, Article No. 376. https://doi.org/10.1186/s12882-021-02583-9
[6]
Leclerc, S., Royal, V., Lamarche, C. and Laurin, L.P. (2021) Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report. American Journal of Kidney Diseases, 78, 607-610. https://doi.org/10.1053/j.ajkd.2021.06.008
[7]
Wu, H.H.L., Kalra, P.A. and Chinnadurai, R. (2021) New-Onset and Relapsed Kidney Histopathology Following COVID-19 Vaccination: A Systematic Review. Vaccines, 9, Article No. 1252. https://doi.org/10.3390/vaccines9111252
[8]
Lai, A.S. and Lai, K.N. (2006) Viral Nephropathy. Nature Clinical Practice Nephrology, 2, 254-262. https://doi.org/10.1038/ncpneph0166
[9]
Leon, L.A.A., Alves, A.D.R., Garcia, R.C.N.C., Melgaço, J.G., de Paula, V.S. and Pinto, M.A. (2017) Parvovirus B19 Infection in a Fatal Case of Acute Liver Failure. The Pediatric Infectious Disease Journal, 36, e355-e358. https://doi.org/10.1097/INF.0000000000001731
[10]
Kauffmann, M., Bobot, M., Daniel, L., Torrents, J., Knefati, Y., Moranne, O., Burtey, S., Zandotti, C. and Jourde-Chiche, N. (2020) Parvovirus B19 Infection and Kidney Injury: Report of 4 Cases and Analysis of Immunization and Viremia in an Adult Cohort of 100 Patients Undergoing a Kidney Biopsy. BMC Nephrology, 21, Article No. 260. https://doi.org/10.1186/s12882-020-01911-9
[11]
Obeidat, M., Isaacson, A.L., Chen, S.J., Ivanovic, M. and Holanda, D. (2020) Zebra-Like Bodies in COVID-19: Is Phospholipidosis Evidence of Hydroxychloroquine Induced Acute Kidney Injury? Ultrastructural Pathology, 44, 519-523. https://doi.org/10.1080/01913123.2020.1850966
[12]
Pintavorn, P. and Cook, W.J. (2008) Progressive Renal Insufficiency Associated with Amiodarone-Induced Phospholipidosis. Kidney International, 74, 1354-1357. https://doi.org/10.1038/ki.2008.229
[13]
Reasor, M.J. and Kacew, S. (2001) Drug-Induced Phospholipidosis: Are There Functional Consequences? Experimental Biology and Medicine, 226, 825-830. https://doi.org/10.1177/153537020122600903
[14]
Mungmunpuntipantip, R. and Wiwanitkit, V. (2021) Zebra-Like Bodies in COVID-19, Hydroxychloroquine, and Acute Renal Injury. Ultrastructural Pathology, 45, Article No. 78. https://doi.org/10.1080/01913123.2020.1866130
[15]
Bril, F., Al Diffalha, S., Dean, M. and Fettig, D.M. (2021) Autoimmune Hepatitis Developing after Coronavirus Disease 2019 (COVID-19) Vaccine: Causality or Casualty? Journal of Hepatology, 75, 222-224. https://doi.org/10.1016/j.jhep.2021.04.003